Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study.

Oral oncology·2025
Same author

Thyroid eye disease: What's the latest?

Cleveland Clinic journal of medicine·2025
Same author

Validation of molecular profiling to preoperatively predict aggressive pathologic features in differentiated thyroid cancer.

Surgery·2025
Same journal

Vocal Fold Opening Position Impacts Bowing Measures in Age-Related Vocal Atrophy.

The Laryngoscope·2026
Same journal

Association Between the Modified Frailty Index and Short-Term Total Thyroidectomy Complications.

The Laryngoscope·2026
Same journal

Discrimination of Pairs of Chemosensory Stimuli in Relation to Respiration.

The Laryngoscope·2026
Same journal

What Safety Precautions Are Recommended When Lasering in the Airway?

The Laryngoscope·2026
Same journal

Success of Anterior Ethmoidal Artery Flaps for Nasal Septal Perforation Repair: A Systematic Review.

The Laryngoscope·2026
Same journal

Laryngeal IgG4-Related Disease: A Systematic Review of Clinical Features and Management.

The Laryngoscope·2026
See all related articles

Related Experiment Video

Updated: Jul 31, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

574

Utilizing Dynamic Risk Stratification in Patients With Tall Cell Variant Papillary Thyroid Cancer.

David Zimmer1, Gilman Plitt2, Brandon Prendes1

  • 1Department of Otolaryngology-Head and Neck Surgery, Head and Neck Institute, Cleveland Clinic, Cleveland, Ohio, U.S.A.

The Laryngoscope
|May 9, 2023
PubMed
Summary
This summary is machine-generated.

Tall cell variant papillary thyroid cancer (TCV PTC) patients with an excellent treatment response show significantly lower recurrence rates. This dynamic risk tool helps predict outcomes for aggressive TCV PTC cases.

Keywords:
papillary thyroid cancerrisk stratificationtall cell variant

More Related Videos

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

845
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.8K

Related Experiment Videos

Last Updated: Jul 31, 2025

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

574
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
04:01

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma

Published on: September 15, 2023

845
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.8K

Area of Science:

  • Endocrinology
  • Oncology
  • Surgical Pathology

Background:

  • Tall cell variant (TCV) papillary thyroid cancer (PTC) is an aggressive subtype associated with poor prognosis.
  • TCV PTC often presents with advanced stage and increased mortality.
  • Effective risk stratification is crucial for managing TCV PTC patients.

Purpose of the Study:

  • To evaluate an established dynamic risk stratification tool in TCV PTC patients.
  • To predict the postoperative course and outcomes for TCV PTC.
  • To assess the tool's efficacy in identifying patients with favorable or unfavorable responses.

Main Methods:

  • Retrospective chart review of 94 TCV PTC patients undergoing total thyroidectomy and radioactive iodine ablation (1998-2020).
  • Assessment of treatment response (biochemical, structural, overall) using postoperative thyroglobulin levels and imaging.
  • Primary outcomes included locoregional/distant recurrence, disease persistence, need for intervention, and disease-specific mortality.

Main Results:

  • Patients with an excellent overall response had significantly lower locoregional recurrence (2.0%) versus other response groups (33.3%-85.7%, p<0.001).
  • Excellent response also correlated with lower distant recurrence (2.0% vs 9.0%-42.9%, p<0.001).
  • An excellent response was associated with reduced disease persistence, fewer interventions, and lower disease-specific mortality.

Conclusions:

  • Despite TCV PTC's aggressive nature, an excellent treatment response predicts significantly improved outcomes.
  • The dynamic risk stratification tool effectively differentiates patient prognoses within the TCV PTC population.
  • This tool aids in tailoring management strategies for TCV PTC based on predicted postoperative course.